Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529

Expert Review of Vaccines

Volumn 2, Issue 2, 2003, Pages 219-229

  Evans, Jay T ^a   Cluff, Christopher W ^a   Johnson, David A ^a   Lacy, Michael J ^a   Persing, David H ^a   Baldridge, Jory R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; AGP; Aminoalkyl glucosaminide 4 phospates; Innate immunity; Monophosphoryl lipid A; MPL adjuvant; RC 529; Ribi.529; TLR4

Indexed keywords

ADJUVANT; CANCER VACCINE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; LIPID A; MALARIA VACCINE; MELACINE; MPL; PHOSPHORYL LIPID A; PNEUMOCOCCUS VACCINE; RC 529; RIBI 529; TOLL LIKE RECEPTOR 4;

ALLERGY; ANTIGEN SPECIFICITY; CANCER; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; HEPATITIS B; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOSTIMULATION; INFECTION; MALARIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REDUCTION; REVIEW; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; TOXICITY;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS; CANCER VACCINES; CELL WALL SKELETON; CLINICAL TRIALS; CORD FACTORS; HEPATITIS B VACCINES; HERPES SIMPLEX VIRUS VACCINES; HUMANS; HYPERSENSITIVITY; LIGANDS; LIPID A; MALARIA VACCINES; MEMBRANE GLYCOPROTEINS; PNEUMOCOCCAL VACCINES; RECEPTORS, CELL SURFACE; SAFETY; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; VACCINES;

EID: 0037654784     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.2.219     Document Type: Review

References (42)

1. Ribi E, Parker R et al. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol. Immunother. 7, 43-58 (1979).
2. Saha DC, Barua RS, Astiz MT et al. Monophosphoryl lipid A stimulated upregulation of reactive oxygen intermediates in human monocytes in vitro. J. Leukoc. Biol. 70(3), 381-385 (2001).
3. De Becker G, Moulin V, Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12(6), 807-815 (2000).
4. Ismaili J, Rennesson J, Aksay E et al. Monophosphoryl lipid A activates both human dendritic cells and T-cells. J. Immunol. 168(2), 926-932 (2002).
5. Persing DH, Coler RN, Lacy MJ et al. Taking Toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10(10), S32-S37 (2002).
6. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 6, 495-524 (1995). Excellent in-depth review of MPL adjuvant.
7. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum, NY, USA, 495-524 (1995).
8. Baldridge JR, Buchmeier MJ. Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J. Virol. 66(7), 4252-4257 (1992).
9. Baldridge JR, Yorgensen Y, Ward JR et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18(22), 2416-2425 (2000).
10. Wijburg OL, van den Dobbelsteen GP, Vadolas J et al. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur. J. Immunol. 28(2), 479-487 (1998).
11. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injection. Allergy 56, 498-505 (2001).
12. Vernacchio L, Bernstein H, Pelton S et al. Effect of monophosphoryl lipid A (MPL™) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM(197) conjugate vaccine in healthy toddlers. Vaccine 20(31-32), 3658-3667 (2002).
13. Baldridge JR. A synthetic adjuvant, RC-529, moves into the clinic. 3rd Meeting on Novel Adjuvants Currently in/close to Human Clinical Testing WHO/TDR - Fondation Merieux, (2002)
14. DuPont J-C, Altclas J et al. Efficacy and safety of AgB/RC529: a novel two dose adjuvant vaccine against hepatitis B. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002).
15. Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16(7), 708-714 (1998).
16. Thoelen S, De Clercq N, Tornieporth NA. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 19(17-19), 2400-2403 (2001).
17. Desombere I, Van der WM, Van Damme P et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 20(19-20), 2597-2602 (2002).
18. Jacques P, Moens G, Desombere I et al. The immunogenicity and reactogenicity profile of a candidate hepatitis 13 vaccine in an adult vaccine non-responder population. Vaccine 20(31-32), 3644-3649 (2002).
19. Stoute JA, Slaoui M, Heppner G, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336(2), 86-91 (1997).
20. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl J. Med. 347(21), 1652-1661 (2002).
21. Corey L, Langenberg AG, Cunningham AL et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4), 331-340 (1999).
22. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20), 5883-5893 (1988).
23. + T-cells from actively immunized melanoma patients. Vaccine Res. 2(1), 41-53 (1993).
24. Mitchell MS, Liggett PE, Green RL et al. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J. Clin. Oncol. 12(2), 396-401 (1994).
25. Mitchell MS, Jakowatz J, Harel W et al. Increased effectiveness of interferon α-2b following active specific immunotherapy for melanoma. J. Clin. Oncol. 12(2), 402-411 (1994).
26. Sosman JA, Unger JM, Harel W et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 20(8), 2067-2075 (2002).
27. Johnson DA, Keegan DS, Sowell CG et al. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem. 42, 4640-4649 (1999).
28. Johnson DA, Sowell CG, Johnson CL et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: Aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett. 9(15), 2273-2278 (1999). Details the synthesis and biological activity of a novel class of synthetic TLR4 agonists.
29. Brandenburg K, Funari SS, Koch MH, Seydel U. Investigation into the acyl chain packing of endotoxins and phospholipids under near physiological conditions by WAXS and FTIR spectroscopy. J. Struct. Biol. 128(2), 175-186 (1999). Importance of lipid A acyl chain length and packing on biological activity.
30. Brandenburg K, Schromm AB, Koch MH, Seydel U. Conformation and fluidity of endotoxins as determinants of biological activity. Prog. Clin. Biol. Res. 392, 167-182 (1995).
31. Seydel U, Labischinski H, Koch MH, Brandenburg K. Phase behavior, supramolecular structure and molecular conformation of lipopolysaccharide. Immunobiology 187(3-5), 191-211 (1993).
32. Brandenburg K, Matsuura M, Heine H et al. Biophysical characterization of triacyl monosaccharide lipid a partial structures in relation to bioactivity. Biophys. J. 83(1), 322-333 (2002).
33. Fukase K, Oikawa M, Suda Y et al. New synthesis and conformational analysis of lipid A: biological activity and supramolecular assembly. J. Endotoxin Res. 5(1/2), 46-51 (1999).
34. Fukuoka S, Brandenburg K, Muller M, Lindner B, Koch MH, Seydel U. Physicochemical analysis of lipid A fractions of lipopolysaccharide from Erwinia carotovora in relation to bioactivity. Biochim. Biophys. Acta 1510(1-2), 185-197 (2001).
35. Han J, Ulevitch RJ. Emerging targets for anti-inflammatory therapy. Nat. Cell Biol. 1(2), E39-E40 (1999).
36. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589(1), 1-13 (2002).
37. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2(10), 947-950 (2001).
38. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145 (2001).
39. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406(6797), 782-787 (2000). Excellent review of the role of TLR in the induction of innate immunity.
40. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 282(5396), 2085-2088 (1998). First identification of a microbial product (LPS) as a TLR agonist.
41. Poltorak A, Riodardi-Castagnoli P et al. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc. Natl. Acad. Sci. USA 97(5), 2163-2167 (2000).
42. Baldridge JR, Cluff C et al. Non-specific resistance and immunostimulatory activity of aminoalkyl glycosaminide 4-phosphates (AGPs): activation of host immune systems by RC-524 and RC-529. J. Endotoxin Res. (2003) (In Press).